2. Stem Cell/Wnt TGF-beta/Smad
  3. TGF-beta/Smad
  4. Luspatercept (mIgG2a)

Luspatercept (mIgG2a)  (Synonyms: RAP-536)

目录号: HY-P99720A
技术支持

Luspatercept (mIgG2a) (RAP-536) 是一种融合蛋白，由修饰的人类 ActRIIB 胞外结构域与鼠类 IgG2a Fc 结构域连接而成。Luspatercept (mIgG2a) 可抑制 β-地中海贫血小鼠中 Smad2/3 信号传导，促进晚期红细胞前体的分化，并缓解无效红细胞生成 (IE)。Luspatercept (mIgG2a) 可减轻贫血、α-珠蛋白聚集、溶血以及铁超载、脾肿大和骨缺损等 IE 疾病并发症。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Luspatercept (mIgG2a) Chemical Structure

Luspatercept (mIgG2a) Chemical Structure

CAS No. : 1373715-00-4

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 是否有货
1 mg   询价  
5 mg   询价  
10 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Luspatercept (mIgG2a):

Luspatercept (mIgG2a) 相关抗体

Top Publications Citing Use of Products

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Luspatercept (mIgG2a) (RAP-536) is a fusion protein, consisting of a modified extracellular domain of human ActRIIB linked to the murine IgG2a Fc domain. Luspatercept (mIgG2a) inhibits Smad2/3 signaling, promotes differentiation of late-stage erythroid precursors and mitigates ineffective erythropoiesis (IE) in murine β-thalassemia. Luspatercept (mIgG2a) reduces anemia, α-globin aggregates, hemolysis, and disease complications of IE such as iron overload, splenomegaly, and bone defects[1].

体内研究
(In Vivo)

Luspatercept (mIgG2a) (RAP-536) (1 mg/kg，皮下注射，每周两次，持续 2 个月) 通过促进 β-地中海贫血小鼠模型中晚期红细胞分化来缓解贫血，减少 α-珠蛋白聚集和溶血，并减轻小鼠的 IE 及相关疾病并发症[1]。
Luspatercept (mIgG2a) (30 mg/kg，腹腔注射，一次，持续 12 小时) 可抑制小鼠 β-地中海贫血小鼠模型中脾脏红细胞前体细胞中 Smad2/3 的过度激活[1]。
Luspatercept (mIgG2a) (1-10 mg/kg，皮下注射，每周两次，持续 2 个月或一次，持续 72 小时) 可促进骨髓和脾脏中的终末红细胞分化，并增加外周红细胞在经 EPO 预处理的野生型小鼠中[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Hbbth1/th1 mice of the B6.D2-Hbbd3th/BrkJ strain (3-4 months old) with hydrogen peroxidenot (50 μM) or not[1].
Dosage: 1 mg/kg
Administration: s.c., twice weekly for 2 months and then collected bone marrow, spleen and liver tissues.
Result: Significantly increased 29% RBC number, 16% hemoglobin concentration, and 19% hematocrit.
Decreased 8% mean cell volume, 10% mean cell hemoglobin, and 2% mean cell hemoglobin concentration.
Reduced 33% reticulocytes and a 19% red cell distribution width area.
Induced an overall increase in the proportion of late-stage erythroid precursors, significantly decreased the cell population of R1 while an increase of R3 in bone marrow, and reduced R1 and R2 with a significant increase in R3 in the spleen.
Reduced ∼60% serum EPO level, 36% splenomegaly, serum concentrations of ferritin (15%) and iron (28%), 29% transferrin saturation.
Reduced iron levels in liver (1464 μg/mg dry weight) and kidney (648 μg/mg dry weight) and altered the iron distribution with restoration of architecture in spleen.
Increased Hamp mRNA levels approximately 2 times without the expression changes of Bmp6 in liver and Gdf15 or Twsg1 in spleen.
Reduced 40% mean concentrations of total bilirubin and occurrence of abnormal erythrocyte morphology and hemolytic debris, but increased mean erythrocyte life span (28 vs 20 days).
Markedly reduced heinz bodies and 38% mean membrane-associated α-globin aggregates in peripheral erythrocytes.
Reduced ROS levels significantly in immature (CD71+Ter119+) and mature (CD71−Ter119+) erythroblasts as well as in peripheral red cells.
Reduced peroxide-stimulated ROS levels and significantly increased 17% bone mineral density, 100% trabecular bone volume (100%), number (14%), and thickness (14%).
Increased cortical thickness with a decrease in marrow space.
Animal Model: Hbbth1/th1 mice of the B6.D2-Hbbd3th/BrkJ strain (3-4 months old)[1].
Dosage: 30 mg/kg
Administration: i.p., once for 12 h, and then collected bone marrow, spleen and liver tissues.
Result: Reduced phosphorylated Smad2/3 level in erythroid precursors of spleens within 12 h.
Inhibited phospho-Smad2 protein expression in erythroid precursors of spleens within 12 h.
Animal Model: C57BL/6 wild-type mice were injected intraperitoneally with EPO (1500 units/kg) or not[1].
Dosage: 1, 10 mg/kg
Administration: s.c., (1 mg/kg) twice weekly for 2 months, (10 mg/kg) once for 72 h, and then collected bone marrow, spleen and liver tissues.
Result: Promoted terminal erythroid differentiation in the bone marrow and spleen and increased peripheral red cells in EPO-pretreated wild-type mice at 10 mg/kg with EPO stimulation in C57BL/6 wild-type mice.
Did not affect iron parameters and Hamp expression in C57BL/6 wild-type mice.
CAS 号
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
参考文献

Luspatercept (mIgG2a) 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Luspatercept (mIgG2a)1373715-00-4RAP-536RAP536RAP 536TGF-beta/SmadTransforming growth factor betaFusion proteinInhibitorIneffective erythropoiesisIEβ-thalassemiaAnemiaα-globin aggregatesHemolysisinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Luspatercept (mIgG2a)
目录号：
HY-P99720A
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z